Latest News - MIGS

Thursday, March 01, 2018

New Data on the CyPass Micro-Stent Presented at the American Glaucoma Society Meeting

Alcon presented new data from the COMPASS Randomized Controlled Trial that reinforce the clinical value of its CyPass Micro-Stent, a microinvasive glaucoma surgery (MIGS) device implanted at the time …

Read the full story

Tuesday, February 27, 2018

International Study Shows Long-Term Titrated IOP Control with 1, 2, or 3 Glaukos iStent Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients

Glaukos announced that implantation of one, two, or three iStent Trabecular Micro-Bypass Stents achieved mean unmedicated IOP reductions of 30%, 37%, and 43%, respectively, at 36 months postoperative.…

Read the full story

Wednesday, January 10, 2018

Glaukos' iDose Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort

Glaukos announced that its travoprost Intraocular Implant with the iDose delivery system continued to provide sustained reduction in IOP in a 12-month interim cohort of patients in its U.S. investigat…

Read the full story

Wednesday, January 03, 2018

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Glaukos announced that it has submitted an investigational device exemption (IDE) application to the FDA seeking authorization to study its iStent infinite Trabecular Micro-Bypass System. The iSte…

Read the full story

Thursday, April 13, 2017

Glaukos Corporation Acquires IOP Sensor System from DOSE Medical

Glaukos announced that it has acquired the IOP sensor system assets and related liabilities from DOSE Medical Corporation for $5.5 million in cash, plus performance-based consideration of up to $9.5 m…

Read the full story

Thursday, April 13, 2017

Sight Sciences Announces Health Canada Approval of the VISCO360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)

Sight Sciences announced that it has received Health Canada approval for the VISCO360 Viscosurgical System. The VISCO360 System is indicated in Canada for the microcatheterization and transluminal vis…

Read the full story

Thursday, March 23, 2017

Ellex to Broadcast ABiC Surgery Event Live From Dean McGee Eye Institute

Ellex Medical will host a live online broadcast of its minimally invasive glaucoma surgery (MIGS) procedure ABiC (ab interno canaloplasty) on Tuesday, March 28, 2017 at the Dean McGee Eye Institute, U…

Read the full story

Thursday, March 16, 2017

Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Microinvasive Glaucoma Surgery

Glaukos announced that the Current Procedural Terminology (CPT) Editorial Panel of the American Medical Association has granted 5-year extensions to three Category III CPT codes that describe insertio…

Read the full story

Thursday, February 16, 2017

Glaukos Completes Patient Enrollment in Pivital Phase of US IDE Clinical Trial for iStent Supra

Glaukos announced the completion of patient enrollment in the pivotal phase of its FDA investigational device exemption (IDE) trial for the iStent Supra Suprachoroidal Micro-Bypass Stent. The iSten…

Read the full story

Tuesday, February 14, 2017

Allergan Announces First Commercial Use of XEN Glaucoma Treatment System in the US

Allergan announced that its XEN Glaucoma Treatment System is now being used by US surgeons to treat refractory glaucoma. The XEN Glaucoma Treatment System, consisting of the XEN45 Gel Stent and the XE…

Read the full story

Monday, December 19, 2016

Number of Glaucoma Cases Projected to Increase Significantly Due To Aging US Population, Prevent Blindness Offers Free Educational Resources

Glaucoma currently affects nearly 3 million people ages 40 and older, according to the Prevent Blindness report, “Future of Vision: Forecasting the Prevalence and Costs of Vision Problems.&rdquo…

Read the full story

Tuesday, November 22, 2016

Allergan Receives FDA Clearance for the XEN Gel Stent, a New Surgical Treatment for Refractory Glaucoma

Allergan announced that the FDA has cleared the XEN Glaucoma Treatment System, which consists of the XEN45 Gel Stent and the XEN Injector. The XEN Glaucoma Treatment System reduces IOP in patients and…

Read the full story

Tuesday, November 08, 2016

New International Study Highlights IOP-Lowering Performance of Glaukos iStent inject Trabecular Micro-Bypass in Standalone Procedure

Glaukos announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open angle glaucoma achieved a ≥ 20% reduction in unmedicated IOP 1 year after implantation of the iS…

Read the full story

Monday, October 31, 2016

Report: iStent Trabecular Micro-Bypass Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patient Population

Glaukos Corporation announced that a study of 134 predominantly Hispanic eyes with open-angle glaucoma (OAG), published in Clinical Ophthalmology, showed mean IOP of 12.9 mm Hg and a 61% decrease in m…

Read the full story

Monday, October 17, 2016

Alcon Launches the CyPass Micro-Stent

Alcon announced the US launch of the CyPass Micro-Stent at the annual meeting of the American Academy of Ophthalmology in Chicago. The CyPass Micro-Stent was approved by the FDA in July for use in con…

Read the full story
Load More